This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2020
  • /
  • 12
  • /
  • Ridgeback Biotherapeutics LP announces the approva...

Ridgeback Biotherapeutics LP announces the approval of Ebanga for Ebola.

Read time: 1 mins
Published:23rd Dec 2020
Ridgeback Biotherapeutics LP a biotechnology company experienced in antiviral drug development, announced that the FDA approved Ebanga (ansuvimab-zykl) for the treatment of Ebola. Ebanga is now approved for treatment of infection caused by Zaire ebolavirus in adult and pediatric patients (including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection). Ebanga is the only FDA approved, single injection Ebola treatment which is available in a lyophilized form. Ridgeback will continue to make Ebanga available to patients who need it. In 2020, Ridgeback initiated a compassionate use protocol for Ebola patients during the DRC’s 11th Ebola outbreak in Équateur Province. Ebanga was provided to all PCR-positive Ebola patients under this protocol.
Condition: Ebola
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.